Are you Dr. Wong?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 14 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
709 N Hill St
Suite 19
Los Angeles, CA 90012Phone+1 213-628-7958Fax+1 213-625-2940
Summary
- Dr. Hing Wong, MD is a family physician in Los Angeles, California. He is currently licensed to practice medicine in California. He is affiliated with Pacific Alliance Medical Center, California Hospital Medical Center, and Garfield Medical Center.
Education & Training
University of California (Irvine)Residency, Physical Medicine and Rehabilitation, 1972 - 1974
St. Johns Riverside HospitalInternship, Transitional Year, 1971 - 1972
National Taiwan University College of MedicineClass of 1969
Certifications & Licensure
CA State Medical License 1977 - 2017
Clinical Trials
- Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome Start of enrollment: 2009 Apr 01
- QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma Start of enrollment: 2010 Feb 01
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
- Join now to see all
Publications & Presentations
PubMed
- 318 citationsT cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activationSarah E. Henrickson, Thorsten R. Mempel, Irina B. Mazo, Bai Liu, Maxim N. Artyomov
Nature Immunology. 2008-01-20 - 191 citationsCD56bright NK cells exhibit potent antitumor responses following IL-15 priming.Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider
The Journal of Clinical Investigation. 2017-10-03 - 269 citationsFirst-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Sarah Cooley, Melissa M. Berrien-Elliott, Peter Westervelt, Michael R. Verneris
Blood. 2018-06-07
Press Mentions
A Novel Immunotherapeutic Approach to Treating Aging-Associated DiseasesApril 3rd, 2023- HCW Biologics Reports Second Quarter Financial Results and Recent Business HighlightsAugust 13th, 2021
Grant Support
- Evaluating Relevant Vaccine Epitopes Displayed On Hiv-Infected CellsNational Institute Of Allergy And Infectious Diseases2011
- Tissue Factor Antagonists For Ali/ArdsNational Heart, Lung, And Blood Institute2011
- Novel IL-15 Superagonist Therapy For Bladder CancerNational Cancer Institute2011
- Bifunctional T Cell Receptor Based ImmunotherapeuticsNational Cancer Institute2004–2011
- Creation Of Tcr-Based Immunotherapeutic Targeting HIV-1National Institute Of Allergy And Infectious Diseases2009
- Transgenic Plant Technology For Producing Therapeutic Recombinant AntibodiesNational Cancer Institute2006–2007
- Soluble T-Cell Receptor Based Tumor Screening ReagentsNational Cancer Institute2004
- T-Cell Receptor Based Therapeutics For CytomegalovirusNational Institute Of Allergy And Infectious Diseases2003
- Bifunctional T Cell Receptor Based ImmunotherapeuticsNational Cancer Institute2002
- T Cell Receptor-Based Immunotherapeutics For CancerNational Cancer Institute2001
